Vol. 2 No. 6 (2022): June
Health Technology Reviews

Cost-Effectiveness of Second-Generation Injectable Antipsychotic Drugs

Published June 7, 2022

Key Messages

  • For adults with bipolar I disorder, the second-generation antipsychotic injectable drug aripiprazole is less costly and more effective over a patient’s lifetime, compared to the second-generation antipsychotic oral drug cariprazine. For adults with bipolar I disorder, aripiprazole injections are more effective compared to the second-generation antipsychotic oral drug asenapine; the cost-effectiveness over a patient’s lifetime depends on the willingness to pay. These results are based on 1 economic evaluation.
  • No cost-effectiveness studies were found comparing second-generation to first-generation antipsychotic injectable drugs.